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ABSTRACT: The key mevalonate pathway enzyme 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reduc-
tase (HMGR) uses the cofactor NAD(P)H to reduce HMG-
CoA to mevalonate in the production of countless metabolites
and natural products. Although inhibition of HMGR by statin
drugs is well-understood, several mechanistic details of
HMGR catalysis remain unresolved, and the structural basis
for the wide range of cofactor speciﬁcity for either NADH or
NADPH among HMGRs from diﬀerent organisms is also
unknown. Here, we present crystal structures of HMGR from
Streptococcus pneumoniae (SpHMGR) alongside kinetic data of
the enzyme’s cofactor preferences. Our structure of SpHMGR
bound with its kinetically preferred NADPH cofactor suggests how NADPH-speciﬁc binding and recognition are achieved. In
addition, our structure of HMG-CoA-bound SpHMGR reveals large, previously unknown conformational domain movements
that may control HMGR substrate binding and enable cofactor exchange without intermediate release during the catalytic cycle.
Taken together, this work provides critical new insights into both the HMGR reaction mechanism and the structural basis of
cofactor speciﬁcity.
HMGR catalyzes the rate-limiting step of the mevalonate
pathway, which is found in all kingdoms of life and is
responsible for the biosynthesis of an enormously wide range
of molecules, from steroids such as cholesterol to isoprenoids,
which make up the largest and most diverse class of natural
products. Its key role in the biosynthesis of steroids makes
HMGR the target of cholesterol-lowering statin drugs. HMGR
performs the four-electron reduction of HMG-CoA to
mevalonate and CoA using 2 equiv of the redox cofactor
NAD(P)H. The enzyme has evolved into two distinct
classes,1−3 where class I HMGRs are present in eukaryotes
and in some bacteria and archaea, while class II enzymes are
found in only bacteria and archaea. Although both HMGR
classes exhibit similar overall folds, with active sites located at a
homodimeric interface, there are many signiﬁcant diﬀerences,
including those in catalytic regions of the protein.2
Class I and class II HMGRs also diﬀer in their NAD(P)H
cofactor preferences: although all class I HMGRs, including
the human enzyme, utilize NADPH exclusively, class II
HMGRs display a wide range of cofactor speciﬁcities. Some
class II enzymes use only NADH, including the HMGRs from
Pseudomonas mevalonii (PmHMGR)4 and Burkholderia cen-
ocepacia,5 while others use only NADPH, such as HMGR from
Enterococcus faecalis.6 Other class II HMGRs are able to use
both NADH and NADPH, often with weak or strong
preferences for one cofactor or the other, including HMGRs
from Staphylococcus aureus,7 Listeria monocytogenes,8 and
Archaeoglobus fulgidus.9
Despite the fact that HMGR inhibition by statins is well-
understood, the molecular details of the HMGR catalytic
mechanism remain somewhat enigmatic.10 Current proposals
suggest that HMG-CoA is ﬁrst reduced to a mevaldyl-CoA
intermediate using the ﬁrst equivalent of NAD(P)H. The order
of the next two steps is uncertain. Oxidized NAD(P)+ must be
exchanged for a second equivalent of NAD(P)H, and
mevaldyl-CoA is also cleaved to form a mevaldehyde
intermediate and CoA. Lastly, mevaldehyde is reduced to
mevalonate by the second NAD(P)H, and the ﬁnal products
are released.
Interestingly, HMGR can also produce mevalonate if
provided with its mevaldyl-CoA or mevaldehyde intermedi-
ates,11,12 skipping the ﬁrst reduction step. However, when
HMG-CoA is the substrate, neither intermediate is released
during the catalytic cycle;10,13−15 instead, the enzyme waits
until the second reduction step is complete to release the ﬁnal
products. How HMGR is able trigger and accomplish cofactor
exchange during the reaction without releasing the bound
intermediates is not known. In addition, the structural basis for
class II HMGR’s wide range of cofactor speciﬁcity is also
unclear. Greater knowledge of the structural features that
control substrate and cofactor binding in class II HMGR not
only would provide insight into its catalytic mechanism but
Received: October 3, 2017
Published: December 11, 2017
Article
pubs.acs.org/biochemistryCite This: Biochemistry 2018, 57, 654−662
© 2017 American Chemical Society 654 DOI: 10.1021/acs.biochem.7b00999
Biochemistry 2018, 57, 654−662
also may enable the development of drugs that target this
crucial metabolic enzyme in human pathogens.
To date, crystal structures for only two class II HMGRs have
been determined, namely, the NADH-speciﬁc PmHMGR and
HMGR from the major human pathogen Streptococcus
pneumoniae (SpHMGR). SpHMGR inhibition has been
previously studied,16 but its cofactor preferences have not
been determined until now. For PmHMGR, many structures
are available,17−19 including the ternary complex depicting the
enzyme bound simultaneously with both the cofactor in its
oxidized form, NAD+, and the substrate HMG-CoA [Protein
Data Bank (PDB) entry 1QAX] or the substrate analogue
dithio-HMG-CoA (PDB entry 4I4B). For SpHMGR, two
structures have been determined in the absence of any bound
ligands (PDB entries 3QAE and 3QAU). Interestingly, a C-
terminal domain that is disordered in the vast majority of
HMGR structures, indicating a high degree of domain
mobility, was ordered in structures of the PmHMGR ternary
complex and apo-SpHMGR. Here, the C-terminal domain in
apo-SpHMGR was ﬂipped away from the substrate- and
cofactor-binding sites, giving rise to an “open” conformation,
while the C-terminal domain in the PmHMGR ternary
complex was positioned directly over the substrate- and
cofactor-binding sites in a “closed” conformation (Figure 1),
where the C-terminal domain contributes a catalytically
essential histidine, as indicated by mutagenic and structural
studies.18,20,21 By alternating between “open” and “closed”
conformations, the C-terminal domain might be capable of
acting as a “ﬂap” to cover the active site when the substrate
and/or cofactor is bound.18 However, when, how, and what
triggers this C-terminal domain movement during the reaction
are unknown.
To gain mechanistic insight into HMGR catalysis and to
shed light on how substrate binding and cofactor binding
inﬂuence the enzyme’s structure during the reaction, we ﬁrst
determined the cofactor preferences of SpHMGR and found
that although the enzyme can use both NADH and NADPH to
reduce HMG-CoA, it has a strong kinetic preference for
NADPH. We also determined two crystal structures of
SpHMGR, one bound with substrate HMG-CoA and one
bound with its preferred cofactor NADPH, which represents
the ﬁrst structure of an NADPH-bound class II HMGR. These
crystal structures not only provide new structural insight into
HMGR cofactor binding and speciﬁcity but also reveal new C-
terminal domain conformations, allowing us to illuminate the
structural movements that enable HMGR reactivity.
■ MATERIALS AND METHODS
Cloning, Expression, and Puriﬁcation. A codon-
optimized, linear mvaA gene that encodes SpHMGR
(Integrated DNA Technologies) was cloned into a modiﬁed
pET28b plasmid termed pSKB3, which encodes an N-terminal,
TEV protease-cleavable hexahistidine tag and a kanamycin
resistance cassette, using NdeI and BamHI restriction enzymes.
The plasmid was transformed into Escherichia coli DH10B
cells, and its gene sequence was conﬁrmed (Quintara
Biosciences) before its transformation into BL21(DE3) cells
for protein expression.
Cells were grown in lysogeny broth supplemented with
kanamycin at 37 °C until OD600 reached ∼0.6. Protein
expression was induced with 0.5 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and proceeded for 18 h at 16
°C. Cells were harvested by centrifugation at 5000g for 10 min,
ﬂash-frozen in liquid nitrogen, and stored at −80 °C. Cells
were resuspended in lysis buﬀer [50 mM Tris (pH 7.7), 200
mM NaCl, 10% glycerol, and 10 mM imidazole] with 0.5 unit/
μL benzonase (Millipore) and 0.5 mM phenylmethanesulfonyl
ﬂuoride (PMSF) and lysed by sonication on ice at 40%
amplitude for 9 min with 3 s bursts and 5 s rests. The lysate
was clariﬁed by centrifugation at maximum speed (∼37000g)
for 30 min at 4 °C, and the supernatant was applied to a Ni-
NTA column equilibrated with lysis buﬀer. SpHMGR was
eluted from the column in fractions using lysis buﬀer with 300
mM imidazole and assessed for purity by SDS−PAGE.
Fractions containing the highest purity were pooled;
hexahistidine-tagged TEV protease was added to cleave the
hexahistidine tag from SpHMGR, and the sample was dialyzed
overnight at 4 °C against 50 mM Tris (pH 7.7), 200 mM
NaCl, 10% glycerol, and 0.5 mM EDTA. The sample was run
over a second Ni-NTA column using lysis buﬀer to purify
cleaved SpHMGR. The protein was further puriﬁed by gel
ﬁltration on a HiLoad 16/600 Superdex 200 prep grade
column (GE Healthcare Life Sciences) equilibrated with 50
mM Tris (pH 7.7), 200 mM NaCl, and 10% glycerol using an
Akta Pure chromatography system (GE Healthcare Life
Sciences). Puriﬁed SpHMGR was concentrated to 15 mg/
mL, ﬂash-frozen dropwise in liquid nitrogen, and stored at −80
°C.
Kinetic Characterization. The cofactor speciﬁcity was
assessed kinetically using a NanoDrop 2000c spectrophotom-
eter (ThermoFisher). Each 100 μL reaction mixture at 37 °C
contained 50 mM Tris (pH 7.4), 50 mM NaCl, 300 μM
HMG-CoA, and 25−500 μM NAD(P)H. Reactions were
initiated by the addition of 20 nM SpHMGR for NADPH
reactions or 100 nM SpHMGR for NADH reactions. Enzyme-
catalyzed oxidation of NAD(P)H was monitored via a decrease
in absorbance at 340 nm, using an extinction coeﬃcient of
6200 M−1 cm−1. The Michaelis−Menten constant, Km, and the
maximum velocity, Vmax, for the production of mevalonate
were determined using nonlinear regression by ﬁtting the
reaction velocities to the Michaelis−Menten equation in
GraphPad Prism 6.0. The values for kcat were obtained by
dividing Vmax by the molar enzyme concentration. Values are
Figure 1. Structures of “open” and “closed” class II HMGR. Aligned
crystal structures of apo-SpHMGR (PDB entry 3QAU) and the
substrate- and cofactor-bound PmHMGR ternary complex (PDB
entry 1QAX), representing “open” (blue) and “closed” (green)
conformations of the C-terminal domain (rmsd for Cα atoms of 0.80).
Structures were aligned with their C-terminal domains excluded. The
cofactor and substrate are labeled and shown as sticks, with C colored
green, N colored blue, O colored red, P colored orange, and S colored
yellow.
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given as the means ± the standard error of the mean (SEM)
from triplicate experiments.
Crystallization. Crystallization conditions for HMG-CoA-
bound SpHMGR were identiﬁed by sparse-matrix screening by
sitting-drop vapor diﬀusion using a Crystal Gryphon (Art
Robbins Instruments) with 10 mg/mL SpHMGR and 1 mM
HMG-CoA. Crystals were observed under condition 17 of
Crystal Screen 1 (Hampton Research), which contains 100
mM Tris (pH 8.5), 200 mM lithium sulfate, and 30%
polyethylene glycol (PEG) 4000. Crystallization conditions
were optimized by hanging-drop vapor diﬀusion with varying
lithium sulfate and PEG 4000 concentrations, and small
crystals grew overnight. Crystals were washed in mother liquor,
crushed via vortexing, and used as seeds for microseeding.
Seeded drops contained 1.0 μL of 10 mg/mL SpHMGR with 1
mM HMG-CoA, 0.8 μL of crystallization solution, and 0.2 μL
of the seed stock. Large crystals grew in 100 mM Tris (pH
8.5), 100−250 mM lithium sulfate, and 15−25% PEG 4000.
The crystals were cryoprotected using the crystallization
solution supplemented with 20% glycerol and 1 mM HMG-
CoA before being ﬂash-cooled in liquid nitrogen.
NADPH-bound SpHMGR crystals grew under the same
crystallization condition that was used for the HMG-CoA-
bound SpHMGR crystals. However, a new crystal form that
took several weeks to grow appeared to use the HMG-CoA-
bound SpHMGR microcrystals as nucleation sites for crystal
growth. These rod-shaped crystals were optimized using the
seeding protocol described above and co-crystallized with 2.5
mM NADPH. Large crystals grew in 100 mM Tris (pH 8.5),
100−250 mM lithium sulfate, and 30−40% PEG 4000. The
crystals were cryoprotected using the crystallization solution
supplemented with 20% glycerol and 5 mM NADPH before
being ﬂash-cooled in liquid nitrogen.
X-ray Data Collection, Structure Determination, and
Reﬁnement. X-ray diﬀraction data were collected at
Advanced Photon Source (APS) beamline 24-ID-E. The data
were indexed, merged, and scaled using iMOSFLM22 in space
group P1 with four molecules in the asymmetric unit for the
NADPH-bound structure and space group P21 with two
molecules in the asymmetric unit for the HMG-CoA-bound
structure. Structures were determined by molecular replace-
ment using Phaser23 in the PHENIX suite,24 where the apo-
SpHMGR structure (PDB entry 3QAE) with unresolved C-
terminal domains was used as the search model. Electron
density maps indicated that the C-terminal domains were
located in novel locations for both structures. Therefore, they
were built manually in Coot25 with iterations of reciprocal
space reﬁnement using phenix.reﬁne.26 After the structures
were determined, we noticed that our protein contained a
V355E mutational artifact. As this site is quite distant from the
cofactor- and substrate-binding sites (>20 Å) as well as the C-
terminal domains (>35 Å), we believe that this is unlikely to
have a signiﬁcant impact on the main ﬁndings of this paper.
■ RESULTS
Kinetic Characterization of SpHMGR. Previous studies
of SpHMGR focused on enzyme inhibition and characterized
the activity using NADPH but did not examine cofactor
speciﬁcity.16 To determine the cofactor preference of
SpHMGR, we measured steady-state kinetics with varying
concentrations of either NADH or NADPH (Table 1). With
respect to NADPH, SpHMGR has a Km of 28.9 ± 5.1 μM and
a kcat of 6.85 ± 0.3 s
−1. With NADH, the enzyme has a Km of
153 ± 59.3 μM and a kcat of 0.131 ± 0.02 s
−1. The resulting
catalytic eﬃciencies (kcat/Km) are 2.4 × 10
5 M−1 s−1 for
NADPH and 8.6 × 102 M−1 s−1 for NADH. These data show
that although SpHMGR can use either cofactor for HMG-CoA
reduction, NADPH is the preferred cofactor by approximately
280-fold in terms of kcat/Km, with both a lower Km and a higher
kcat for NADPH compared with those of NADH.
Overall Structures. SpHMGR bound to its preferred
cofactor NADPH crystallized in the P1 space group with four
molecules in the asymmetric unit, arranged as two homodimers
(chains A and B and chains C and D). The overall structure is
nearly identical to the prior apo-SpHMGR structures (PDB
entries 3QAE and 3QAU), except for the C-terminal domains,
detailed below, with root-mean-square deviations for Cα atoms
(rmsd’s) of 0.23−0.25. Clear electron density was observed for
all four monomers of the asymmetric unit, except the C-
terminal domains (residues 375−424) of chains A and C were
disordered. Electron density in these regions was weak and
discontinuous, and thus, we did not model the C-terminal
domains for chains A and C. Therefore, in the ﬁnal model,
chains A and C contain residues 3−372 of 424 while chains B
and D contain residues 11−424 and 3−424, respectively. In
addition, positive diﬀerence maps showed density in the
cofactor-binding sites of both chains A and C, representing
NADPH binding. For chain A, clear electron density for
NADPH was observed, including for the key 2′-phosphate
group, though it may be noted that the 2′-phosphate density is
partially discontinuous with the rest of the NADPH molecule
(Figure 2A), suggesting a small degree of disorder. For chain
C, however, electron density for NADPH was signiﬁcantly
Table 1. SpHMGR Cofactor Preferences
NADPH NADH
Km (μM) 28.9 ± 5.1 153 ± 59.3
kcat (s
−1) 6.85 ± 0.3 0.131 ± 0.02
kcat/Km (M
−1 s−1) 2.4 × 105 8.6 × 102
Figure 2. NADPH- and HMG-CoA-binding sites of SpHMGR, with
mFO − DFC omit density for (A) NADPH and (B) HMG-CoA bound
to SpHMGR (PDB entries 5WPJ and 5WPK, respectively). The
protein is shown as a gray cartoon; NADPH and HMG-CoA are
shown as sticks, with C colored green, N colored blue, O colored red,
P colored orange, and S colored yellow. The mFO − DFC polder omit
map is contoured at 3.0σ (pink mesh) and 2.5σ (blue mesh), as
calculated in Phenix.24,33
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weaker and included signiﬁcant negative FO − FC diﬀerence
density around the nicotinamide and adenosine rings. A trial
reﬁnement at 70% occupancy for NADPH mostly satisﬁed the
diﬀerence maps (Figure S1), but because the 2FO − FC maps
remained highly discontinuous, we chose to leave NADPH in
chain C out of the ﬁnal model.
SpHMGR bound to HMG-CoA crystallized in the P21 space
group with two molecules in the asymmetric unit assembled as
a homodimer (chains A and B). The C-terminal domain was
resolved only in chain B; therefore, in the ﬁnal model, chain A
contains residues 1−379 while chain B contains residues 3−
424. Electron density maps showed clear density for HMG-
CoA in the substrate-binding sites of both chains (Figure 2B).
Complete X-ray diﬀraction and reﬁnement statistics are listed
in Table 2.
In the obligate HMGR homodimer, the larger N-terminal
domain, which includes the active site, forms a majority of the
dimer interface. Interestingly, the interface contains an
interlocking motif where residues 1−69 cross and intertwine
with each other through loops formed by residues 38−58,
forming an interlocked β-sheet that contains several conserved
residues and has been observed in prior structures of HMGR
(Figure S2A,B).27,28 This region is also involved in substrate
binding, as in our HMG-CoA-bound SpHMGR structure
Glu50 and Asn51 from the interlocking loop of one monomer
interact with the adenine ring of HMG-CoA bound by the
adjacent monomer (Figure S2C).
Substrate- and Cofactor-Binding Sites. The HMG-CoA
substrate and the NAD(P)H cofactor are both long molecules
that bind HMGR with their reactive groups pointing toward
each other in the buried active site core at the homodimeric
interface and with the rest of the molecules extending out from
the active site in diﬀerent directions, together resembling a “V”
shape. Correspondingly, in our structure of HMG-CoA-bound
SpHMGR (Figure 3A), the substrate binds with its reactive
HMG moiety in the active site, with Arg257 forming a salt
bridge with the carboxylate of the HMG moiety, which also
interacts via a water molecule with the backbone carbonyl of
His261 and the side chain of Asn362. The pantothenate group
of HMG-CoA then extends out toward the surface of the
protein, interacting via water molecules with Gln361 and
Ala364. HMG-CoA reaches the protein surface at its
diphosphate group, which interacts with Lys380 and Lys384,
both from the C-terminal domain. Finally, the adenosine group
of HMG-CoA lies on the surface of the protein, with its
adenine ring interacting with the interlocked Glu50 and Asn51
of the opposite monomer, as mentioned above. In addition, the
3′-phosphate of the adenosine ribose forms hydrogen bonds
with the backbone NH group of Gly7 as well as the side chain
and backbone NH group of Ser9. Interestingly, Ser9 also forms
a hydrogen bond with the same Lys384 of the C-terminal
domain that interacts with the substrate diphosphate, as
described. Though distant in primary sequence, this Ser9−
Lys384 interaction thus “bridges” the 3′-phosphate and the
diphosphate groups of HMG-CoA. In addition, there are
several hydrophobic interactions between the pantothenate
Table 2. Data Collection and Reﬁnement Statisticsa
NADPH-bound
SpHMGR
HMG-CoA-bound
SpHMGR
PDB entry 5WPJ 5WPK
Diﬀraction Data
beamline APS, 24-ID-E APS, 24-ID-E
wavelength (Å) 0.9792 0.9792
space group P1 P21
unit cell dimensions
a, b, c (Å) 58.0, 84.0, 94.2 57.9, 131.2, 57.9
α, β, γ (deg) 108.2, 100.6, 109.1 90.0, 102.5, 90.0
resolution range (Å) 72.72−2.00
(2.072−2.00)
19.23−2.30
(2.382−2.30)
Wilson B (Å2) 20.86 23.56
total no. of reﬂections 201205 (20446) 129322 (12606)
no. of unique
reﬂections
95302 (9432) 36792 (3643)
multiplicity 2.1 (2.2) 3.5 (3.5)
completeness (%) 93.23 (92.35) 98.17 (97.98)
mean I/σ(I) 5.02 (1.88) 6.48 (1.84)
Rmerge 0.1159 (0.4474) 0.1514 (0.5832)
Rmeas 0.1556 (0.6014) 0.1788 (0.6913)
CC1/2 0.984 (0.436) 0.987 (0.676)
CC* 0.996 (0.779) 0.997 (0.898)
Reﬁnement
Rwork 0.1635 (0.2813) 0.1771 (0.2452)
Rfree 0.2236 (0.3245) 0.2333 (0.3234)
no. of protein/ligand
atoms
13644 6617
rmsd for bonds (Å) 0.008 0.003
rmsd for angles (deg) 1.243 0.627
average B factor (Å2) 24.0 29.0
Ramachandran analysis
(%)
favored 97.72 96.87
allowed 1.90 3.13
outliers 0.38 0
MolProbity Clashscore 9.33 6.19
aStatistics for the highest-resolution shell are shown in parentheses.
Figure 3. Interactions between SpHMGR and its substrate and
cofactor. (A) HMG-CoA- and (B) NADPH-binding sites of
SpHMGR. Protein amino acids (C colored gray) and all bound
ligands (C colored green) are shown as sticks, with N colored blue, O
colored red, P colored orange, and S colored yellow, and water is
shown as spheres. Dashed lines represent hydrogen bonds.
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and β-mercaptoethylamine moieties of HMG-CoA and the
enzyme, including its C-terminal domain.
In our NADPH-bound SpHMGR structure (Figure 3B),
only one NADPH molecule is included in the ﬁnal model.
Although the active site lies at the dimer interface, the cofactor
interacts almost exclusively with the opposite monomer as
HMG-CoA. As with the substrate, the cofactor binds with its
reactive group buried in the active site. Here, the amide group
of the nicotinamide ring hydrogen bonds with Asn212, while
the 2′-OH group of the nicotinamide’s ribose hydrogen bonds
with Asp279. From here, the cofactor, like the substrate,
extends out toward the protein surface and reaches the solvent
at its diphosphate moiety, which interacts directly or through
bridging water molecules with the backbone NH groups of
Met181, Gly182, Ala183, and Asn184. Together, these four
residues form the N-terminal cap of a helix and its preceding
loop. The NADPH adenosine group is solvent-exposed, with
the adenine ring sandwiched between stacking Lys325 and
Arg150 side chains. Intriguingly, Arg150 also forms a salt
bridge with the critical 2′-phosphate of NADPH, which also
interacts with Ser146 (Figure 3B).
C-Terminal Domain. In our NADPH-bound SpHMGR
structure, the resolved C-terminal domains of chains B and D
are both positioned in “open” conformations, in that they are
ﬂipped away from the active site, leaving the substrate- and
cofactor-binding sites exposed. However, the C-terminal
domains in this structure adopt “open” conformations slightly
diﬀerent from each other (Figure 4A, light and dark orange).
Moreover, neither conformation aligns with the previously
observed “open” C-terminal domain of the apo-SpHMGR
structure (PDB entry 3QAU) (Figure 4A, blue). These
variations in “open” C-terminal domain conformations appear
to be caused by interactions with adjacent molecules in the
crystal.
On the other hand, the C-terminal domain in our HMG-
CoA-bound SpHMGR structure is observed in an entirely new
position (Figure 4B). Although ﬂipped more toward the active
site relative to the “open” conformations, the C-terminal
domain is not positioned over the cofactor-binding site, as was
previously observed in the “closed” structures of the
PmHMGR ternary complex (Figure 4B). In the “closed”
conformation, the C-terminal domain covers both the
substrate and the cofactor (Figure 4B, bottom panel), while
also contacting the N-terminal domain of the adjacent
monomer. Instead, the C-terminal domain in our substrate-
bound SpHMGR structure is rotated by approximately 90°
from the N-terminal domain of the adjacent monomer and
from the cofactor-binding site, as well. In this new position, the
C-terminal domain still covers the substrate-binding site;
indeed, C-terminal domain residues Lys380 and Lys384 both
directly interact with the CoA portion of the substrate (Figures
3A and 5), as described above. Therefore, we term this novel
position the “partially closed” conformation of the C-terminal
domain, which covers the substrate-binding site while leaving
the cofactor-binding site open (Figures 4B and 5). Despite the
C-terminal domain maintaining direct contact with the CoA
moiety in this “partially closed” conformation, the catalytic
histidine (His378 in SpHMGR) is lifted slightly and tilted
away from CoA compared with that in the “closed” PmHMGR
ternary structure (Figure S3).
■ DISCUSSION
HMGR is a key enzyme in the mevalonate pathway, which is
responsible for the biosynthesis of a wide range of molecules,
from cholesterol and other steroids to isoprenoid natural
products, many of which have medicinal or other uses as
commodity chemicals. In particular, microbial class II HMGRs
display a wide range of NAD(P)H cofactor speciﬁcities, where
some enzymes use either NADH or NADPH exclusively, while
others can employ both cofactors to reduce HMG-CoA to
mevalonate and CoA. Cofactor usage is a great concern in
Figure 4. Conformational movements of the C-terminal domain. (A)
Alignment of apo-SpHMGR (PDB entry 3QAU) with chain B and
chain D of the NADPH-bound SpHMGR structure, with C-terminal
domains colored blue, light orange, and dark orange (rmsd’s of 0.23
and 0.25). (B) Alignment of HMG-CoA-bound SpHMGR, with the
C-terminal domain colored teal, with the HMG-CoA- and NAD+-
bound PmHMGR ternary complex (PDB entry 1QAX), with the C-
terminal domain colored green (rmsd of 0.89). (C) Overlay of panels
A and B. Proteins are shown as gray cartoons, except for C-terminal
domains. All ligands are shown as sticks, with C colored green, N
colored blue, O colored red, P colored orange, and S colored yellow.
Figure 5. Close-up view of the class II HMGR C-terminal domain in
the “closed” conformation colored green (from the PmHMGR ternary
complex, PDB entry 1QAX) and the “partially closed” conformation
colored teal (from the HMG-CoA-bound SpHMGR presented here,
PDB entry 5WPK) from Figure 4B (bottom panel). Salt bridge and
hydrogen bonding interactions between the “partially closed” C-
terminal domain and the HMG-CoA substrate are shown as dashed
lines.
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metabolic engineering for the production of commodity
chemicals, including isoprenoid-derived drugs and biofuels,29,30
to ensure and maintain redox balance and the availability of the
correct reductant, either NADH or NADPH. Therefore, a
better understanding of the HMGR reaction mechanism and
cofactor speciﬁcity may lead to the development of HMGR
variants whose cofactor preferences are optimized to address
issues of redox balance in microorganisms engineered for
isoprenoid production via the mevalonate pathway.31 In
addition, greater insight into the reaction mechanism and
cofactor preferences of class II HMGR could lead to the
development of novel antibiotics, as class II HMGRs are
present only in bacteria and archaea. Indeed, the mevalonate
pathway has been shown to be essential for growth in many
pathogenic microorganisms, including S. pneumoniae, a major
cause of pneumonia.32
We demonstrate here that class II HMGR from S.
pneumoniae can utilize both NADPH and NADH, but with a
strong preference for NADPH (kcat/Km of 2.4 × 10
5 M−1 s−1
for NADPH vs 8.6 × 102 M−1 s−1 for NADH). Therefore, we
determined the crystal structure of SpHMGR in the presence
of NADPH to better understand the structural basis of cofactor
speciﬁcity, representing the ﬁrst structure of a class II HMGR
bound to NADPH.
In a prior structure of NADH-bound PmHMGR,18 Asp146
hydrogen bonds with the NADH adenosine 2′-OH group,
presumably preventing the larger and negatively charged 2′-
phosphate of NADPH from binding to the enzyme. This
observation led to the possibility that Asp146 confers cofactor
speciﬁcity in PmHMGR; however, its mutation to alanine,
glycine, asparagine, or serine did not switch the cofactor
preference,4 as the catalytic eﬃciency, kcat/KM, for NADH was
still 10−1000-fold greater than for NADPH, indicating that
Asp146 in PmHMGR is not solely responsible for cofactor
speciﬁcity.
Surprisingly, in structures of NADPH-preferring SpHMGR,
Asp146 of PmHMGR is not replaced by a smaller or positively
charged residue to accommodate the 2′-phosphate of NADPH,
but with a bulky and neutral residue (Tyr144). In fact, we
observe that Asp146 of PmHMGR and Tyr144 of SpHMGR
are both the ﬁrst amino acids of a short, seven-residue
conserved helix that binds the NAD(P)H cofactor at its
adenosine moiety (Figure 6). This helix, which we term the
“cofactor helix”, has a completely diﬀerent sequence in
PmHMGR (residues 146−152) and SpHMGR (residues
144−150) (DQLLNSL and YPSIVKR, respectively).
Because of its preference for NADPH over NADH, replacing
Asp146 of PmHMGR with the bulkier and uncharged Tyr144
of SpHMGR may at ﬁrst seem counterintuitive. However, in
our cofactor-bound SpHGMR structure, Tyr144 prevents the
NADPH adenosine ribose from occupying the same space as
observed with NADH in PmHMGR (Figure 6). Instead,
because of the large size of tyrosine, the NADPH adenosine is
shifted in the cofactor-binding site compared to NADH in
PmHMGR. Though the nicotinamide rings and the
diphosphates of NADH and NADPH align well between the
PmHMGR and SpHMGR structures, the phosphoribose in
SpHMGR is shifted by ∼3.0 Å, causing the adenine ring also to
be displaced by ∼2.0 Å. Therefore, it appears unlikely that
NADPH of SpHMGR could occupy the same space as NADH
in PmHMGR, because of the steric hindrance of Tyr144. As a
result, Tyr144 blocks phosphoribose from getting close to the
start of the cofactor helix, thus providing space for the 2′-
phosphate to interact with Ser146 instead, which is located
toward the center of the cofactor helix. In fact, this serine
residue appears to be highly conserved among HMGRs that
prefer NADPH, while HMGRs that prefer NADH have a
hydrophobic residue at this position (Figure 7), such as
Leu148 in PmHMGR. Furthermore, the adenosine ribose of
NADPH has shifted enough to allow Arg150 at the end of the
SpHMGR cofactor helix to play a dual role by interacting with
both the 2′-phosphate and the adenine ring, as described
above. However, in NADH-preferring HMGRs, a hydrophobic
residue is often found in this position instead of arginine
(Figure 7), such as Leu152 in PmHMGR.
Taken together, these structural observations suggest that
several residues of the cofactor helix contribute to NADPH
binding and recognition in class II HMGRs. In SpHMGR, the
bulky Tyr144 causes a shift in the location of the adenosine
moiety of NADPH as compared to that of NADH in
PmHMGR (Figure 6). This shift allows the 2′-phosphate of
NADPH to interact with both conserved Ser146 in the center
of the cofactor helix and conserved Arg150 at the end of the
helix, which also stacks with the NADPH adenine ring. With
these NADPH-binding features now described, future studies
to modify this region may oﬀer additional insight into how
cofactor speciﬁcity may be controlled or engineered.
In addition, our SpHMGR structures reveal large conforma-
tional changes upon substrate binding. The C-terminal domain
is disordered and absent in most HMGR crystal structures but
has been visualized in the structures of apo-SpHMGR and the
ternary PmHMGR complex, bound simultaneously with both
the cofactor and substrate or substrate analogue. These studies
indicated that this domain may act as a ﬂexible ﬂap that can
open and close over the active site at some point during the
reaction.18 In our NADPH-bound SpHMGR structure, the two
resolved C-terminal domains are positioned in “open”
conformations that are slightly diﬀerent from each other
(Figure 4A), likely because of crystal packing. This suggests
that the C-terminal domain does not occupy a single, rigid
“open” conformation but is ﬂexible and can sample many
possible “open” positions that are all distant from the cofactor-
and substrate-binding sites. Such ﬂexibility also explains why
this domain is often unresolved in HMGR crystal structures.
Importantly, these “open” conformations are observed
regardless of whether the cofactor is bound, as in our
NADPH-bound structure, or unbound, as in the prior apo-
SpHMGR structure (PDB entry 3QAE). Indeed, the partial
occupancy for NADPH observed in chain C of our NADPH-
Figure 6. Comparison of NADH and NADPH cofactor-binding sites
of class II HMGR. Alignment of the HMG-CoA- and NAD+-bound
PmHMGR ternary complex (green, with residue labels in green) with
the NADPH-bound SpHMGR structure (gray, with residue labels in
black). The “cofactor helix” is labeled, and dashed lines represent
hydrogen bonds.
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bound structure and the slightly weaker density for NADPH in
chain A are consistent with the notion that these “open”
conformations allow for cofactor entry and exit.
Although NADPH binding alone does not appear to trigger
movement of the C-terminal domain to the “closed”
conformation, in our substrate-bound SpHMGR structure
the C-terminal domain adopts a new, “partially closed”
conformation (Figure 4B). This structure represents the ﬁrst
visualization the HMGR C-terminal domain in which the
substrate is bound in the absence of the cofactor. Compared to
the fully “closed” conformation depicted in the structures of
the PmHMGR ternary complex,19 the C-terminal domain is
rotated ∼90° away from the cofactor-binding site and toward
the HMG-CoA-binding site (Figure 4B), with multiple
interactions observed between the “partially closed” C-terminal
domain and the CoA moiety. Therefore, in this position, the
cofactor-binding site is left open and accessible while the
substrate-binding site remains closed oﬀ by the C-terminal
domain (Figures 4B and 5).
The discovery of this “partially closed” conformation might
also help to explain how class II HMGRs can undergo cofactor
exchange during the reaction cycle without releasing the
reaction intermediates mevaldyl-CoA or mevaldehyde, by
using a mobile C-terminal domain that adopts multiple
conformations (Figure 4C). In this proposed model, before
substrate binding, the C-terminal domain is “open” and
ﬂexible, regardless of whether the cofactor is bound, as
described above and observed in the prior apo-SpHMGR
structure and the NADPH-bound SpHMGR structure
presented here. When both the substrate and the cofactor
are bound, the C-terminal domain closes over both sites and
contributes a catalytically essential histidine residue, as seen in
structures of the “closed” PmHMGR ternary complex.18,19
After the ﬁrst reduction step that forms NAD(P)+ and the
mevaldyl-CoA intermediate, the C-terminal domain rotates
away from the cofactor-binding site to the new “partially
closed” conformation, which allows for cofactor exchange
while keeping the intermediate bound to the enzyme through a
number of interactions between the C-terminal domain and
the CoA group, as depicted in our HMG-CoA-bound
SpHMGR structure. After cofactor exchange is complete and
the second NAD(P)H molecule binds, the C-terminal domain
can fully close over both cofactor- and substrate-binding sites
again, and the second reduction step can proceed. When the
reaction is complete, the C-terminal domain can swing open
once again to allow for product and cofactor release.
In conclusion, the two crystal structures of SpHMGR
described here provide new insight into both the reaction
mechanism and the structural basis of cofactor preference in
class II HMGR. The crystal structure of NADPH-bound
SpHMGR is the ﬁrst structure of a class II HMGR bound to
NADPH, enabling identiﬁcation and examination of how
residues in the “cofactor helix”, present only in microbial class
II enzymes, contribute to NAD(P)H cofactor binding and
recognition. This structure also demonstrates the inherent
ﬂexibility of the C-terminal domain in the “open” con-
formation, which is observed regardless of whether the cofactor
is bound. Meanwhile, the crystal structure of HMG-CoA
bound to SpHMGR reveals a new “partially closed”
conformation for the C-terminal domain, which suggests
how substrate binding may trigger movement of the C-
terminal domain from the “open” conformation toward the
active site. By covering the substrate-binding site while leaving
the cofactor-binding site open, this “partially closed”
conformation also illuminates the structural basis for how
class II HMGRs can accomplish cofactor exchange during the
reaction without the premature and wasteful release of
intermediates. With these newly identiﬁed conformations of
the enzyme, additional studies, including those that investigate
intermediate binding in HMGR, may be performed to further
probe the conformational landscape of this important enzyme.
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